Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Mirum Pharmaceuticals will present late-breaking Phase 2b data for volixibat in primary sclerosing cholangitis (PSC) and brelovitug in chronic hepatitis delta virus (HDV) at the EASL International Liver Congress 2026. The volixibat VISTAS study results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus, while the brelovitug AZURE-1 study shows efficacy and safety in HDV treatment.
Key figures
- Drug Name
- volixibat, brelovitug, maralixibat
- Phase Of Trial
- Phase 2b
- Conference name
- EASL International Liver Congress 2026
- Conference dates
- May 27-30, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.